Multi-center, randomized, double-blind, placebo-controlled study of two dosages of AM3301 for add-on treatment of mild to moderate active ulcerative colitis.
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2016
At a glance
- Drugs AM 3301 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Kemin Pharma
- 01 Jul 2010 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India record.
- 21 May 2010 New trial record